度洛西汀治疗功能性胃肠病的疗效分析OACSTPCD

Objective To investigate the clinical effect of duloxetine in the treatment of functional gas-trointestinal disorders(FGIDs).Methods Seventy-eight patients with FGIDs treated in this hospital from March 2020 to July 2022 were selected as the research subjects.The patients with the self-rating anxiety scale(SAS)score ≥50 points and self-rating depression scale(SDS)score ≥53 points were divided into the control group and observation group according to block randomization,39 cases in each group.The control group was treated with routine internal medical treatment,and the observation group was treated with duloxetine on the basis of the control group.The course of treatment in the two groups was one month.The psychological sta-tus,gastrointestinal symptoms and adverse reactions before and after treatment were compared between the two groups.Results After treatment,the scores of SAS,SDS and gastrointestinal symptom rating scale(GSRS)in the two groups were lower than those before treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P＜0.05).There were 8 ca-ses(20.51％)of adverse reactions in the control group and 7 cases(17.95％)in the observation group,and the difference was not statistically significant(P＞0.05).No liver and kidney function abnormalities and uri-nary tract systematic diseases were found in both group.Conclusion Duloxetine is effective in the treatment of FGIDs,which could improve the clinical symptoms and psychological symptoms of the patients,and the medication is safe.